ClinicalTrials.gg
RecruitingNCT05635877Updated Mar 29, 2023

Effects of Low-dose Esmolol on Myocardial Injury After Non-cardiac Surgery in Elderly Frail Patients

A Phase 4 interventional study of Esmolol and Placebo Comparator: Placebo Comparator:normal saline(0.9%) in Frailty, Esmolol and Myocardial Injury, sponsored by Yongtao Sun. Recruiting at 1 site in China. Open to participants aged 65 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-03-29.

Sponsored by Yongtao Sun · Phase 4, Interventional, and Other

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
65 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Frailty with a site in China — 26 open to participants now, 28 under way, none of them phase 3. Frailty · China.

Planned enrollment
2nd of 32
2,000 · median 146
Started
2023
with 8 others
Phase 4
2 of 65
2 open now
Primary completion
2026-11
later than 12 of 27 live
Registered
23rd of 65
by date

Among the 65 studies in Frailty with a site in China, this one is the 2nd largest by planned enrollment of the 32 interventional ones that give a count, is one of 9 that started in 2023, is one of 2 in phase 4, reaches primary completion later than 12 of the 27 other live ones, and was the 23rd registered.

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

26 of the 65 studies in Frailty with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.

This study: 65 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Frailty with a site in China, or all of them as a file.
02

Study summary

This topic will focus on the following questions:

  1. Part one: To clarify the relationship between preoperative frailty and myocardial injury (cTnT ≥0.03) after non-cardiac surgery in elderly patients; To further explore the predictive factors of myocardial injury after non-cardiac surgery (MINS) in elderly frail patients before operation.
  2. Part Two: To explore the effect of low-dose esmolol on myocardial injury after non-cardiac surgery in frail elderly patients.
Read the detailed description

Esmol is a short-acting selective β-adrenergic receptor blocker, which is often used in patients with cardiovascular diseases or hypertension. It is also used to reduce stress response, control heart rate and reduce myocardial oxygen consumption during perioperative period to effectively protect cardiac function. However, the safety and efficacy of perioperative β-blockers are still controversial due to their possible effects on renal function. Several recent studies have shown that β-blockers reduce perioperative myocardial ischemia and may reduce the risk of perioperative myocardial infarction (PMI) and cardiovascular death in high-risk patients . The 2021 American College of Cardiology /American Heart Association (ACC/AHA )guidelines for coronary revascularization suggest that dose adjustment can optimize the clinical effects of β-blockers, thereby reducing adverse effects during treatment . In addition, several studies have found that continuous intraoperative infusion of low-dose esmolol (5-10μg/kg/min) can reduce intraoperative stress response and maintain hemodynamic stability. The meta-analysis of esmolol by Ollila A et al. found that esmolol has a promising application in the prevention of perioperative myocardial ischemia and serious complications associated with long-term ischemia. Does perioperative Esmolol reduce the incidence of myocardial injury after non-cardiac surgery (MINS)? The safety, outcome and benefit of perioperative esmolol in frail patients are still unclear. Therefore, this study intends to apply the appropriate dose of esmolol to prevent cardiovascular events in elderly frailty patients undergoing non-cardiac surgery, and explore the effect of low-dose esmolol on MINS in elderly frail patients, so as to provide feasible clinical measures for the safe outcome and rehabilitation of frail patients during perioperative period.

03

Conditions studied

  • Frailty
  • Esmolol
  • Myocardial Injury

Browse trials for

Keywords

  • myocardial injury after non-cardiac surgery, MINS
04

Who can participate

Ages eligible
65 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 65 years;
  2. ASA: ⅰ-ⅳ;
  3. Modified frailty index (mFI) ≥ 0.21;
  4. Patients undergoing non-cardiac surgery.

Exclusion criteria

Exclusion Criteria:

  1. Refuse to participate;
  2. Expected hospital stay \<3 days;
  3. Preoperative β-blocker therapy;
  4. History of myocardial infarction or coronary artery disease;
  5. Preoperative bradycardia (heart rate [HR] \< 50 bpm) or arrhythmia;
  6. Significant cardiac insufficiency (i.e., pulmonary artery pressure >18 mm Hg, cardiac index ≤ 2.2 L/min/m 2);
  7. Severe valvular heart disease;
  8. Severe lung disease (e.g. asthma or );
  9. Patients with perioperative troponin elevation due to nonischemic causes (e.g., sepsis, pulmonary embolism, arrhythmia);
  10. The same patient can only be included once, regardless of whether the reason for the second operation is related to the first cause.

    -

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
2,000 participants (estimated)

Study arms

  • Experimental
    Experimental:Esmolol

    The treatment group was given esmolol 0.5mg/kg load, 10μg /kg/min continuous pump; Patient-controlled analgesia pump (sufentanil 2 μg/kg, 2 mL/h, for 48h) was used as the postoperative analgesia regimen in the two groups. If the VAS score was \>3, analgesic adjuvant drugs were given intravenously and recorded. If repeated treatment is ineffective, the study will be excluded.

    Drug: Esmolol

  • Placebo comparator
    Placebo Comparator:normal saline(0.9%)

    The control group received the same volume of 0.9% normal saline, which was continuously pumped until the end of the operation before extubation.Patient-controlled analgesia pump (sufentanil 2 μg/kg, 2 mL/h, for 48h) was used as the postoperative analgesia regimen in the two groups. If the VAS score was \>3, analgesic adjuvant drugs were given intravenously and recorded. If repeated treatment is ineffective, the study will be excluded.

    Drug: Placebo Comparator: Placebo Comparator:normal saline(0.9%)

Interventions

  • The treatment group was given Esmolol 0.5mg/kg load and 10μg /kg/min continuous pump

  • DrugPlacebo Comparator: Placebo Comparator:normal saline(0.9%)

    The control group received the same volume of 0.9% normal saline, which was continuously pumped until the end of the operation before extubation.Patient-controlled analgesia pump (sufentanil 2 μg/kg, 2 mL/h, for 48h) was used as the postoperative analgesia regimen in the two groups. If the VAS score was \>3, analgesic adjuvant drugs were given intravenously and recorded. If repeated treatment is ineffective, the study will be excluded.

06

What researchers measure

Primary outcomes

  1. incidence of Postoperative myocardial injury after non-cardiac surgery(MINS)

    incidence of Postoperative myocardial injury after non-cardiac surgery(MINS), blood samples were collected at 1 day before surgery and 1, 2, and 3 days after surgery. MINS diagnostic criteria: Blood samples were collected before surgery, 1d, 2d and 3d after surgery for Roche fourth-generation Elecsys hs-TnT detection, cardiac troponin(cTnT) ≥ 0.03 ng/mL, and MINS can be diagnosed.

    Time frame: incidence of MINS within 3 days after operation

Secondary outcomes

  1. the results of 30 days after surgery

    the results of 30 days after surge, demographic characteristics of patients, preoperative disease complications, the treatments number of intraoperative hemodynamic instability , hospital stays, any complications occurring within 30 days after surgery, and readmitted to hospital were recorded. Perioperative MAP \< 65 mmHg or bradycardia (HR) \< 50 times /min in both groups, and no spontaneous remission was found 5 minutes after the operation was stopped, that is, intervention measures were given, including ephedrine, atropine, dopamine and other treatments., demographic characteristics of patients, preoperative disease complications, the number of intraoperative hemodynamic instability treatments, length of stay, any complications occurring within 30 days after surgery, and readmitted to hospital were recorded.

    Time frame: Outcomes at 30 days after operation were recorded

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2023 (actual). Primary completion is estimated for Nov 2026, 45 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2022
First posted
Dec 2, 2022
StartActual
Feb 7, 2023
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Mar 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05635877
Lead sponsor
Yongtao Sun
Responsible party
Yongtao Sun (professor, Qianfoshan Hospital) — Sponsor-investigator
First posted
Dec 2, 2022
Start date
Feb 7, 2023
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Mar 29, 2023

Study contacts

yongtao Sun, PH.D
Contact
sunyongtao1979@163.com
18660795201

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esmolol

Start the discussion